Overview

A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

Status:
Completed

Trial end date:
2019-04-24

Target enrollment:

Participant gender:

Summary

Duavee is a hormone receptor modulator that has been approved for the treatment of menopausal symptoms in menopausal women. The goal of this 8-week randomized, double blind, placebo controlled pilot study, is to determine whether this medication alleviates menopausal symptoms in women with MS. The investigators will secondarily determine whether addressing menopausal symptoms ameliorates MS symptoms and, on MRIs, is not triggering worsening inflammation.

Phase:

Phase 2

Details

Lead Sponsor:

University of California, San Francisco

Collaborator:

National Multiple Sclerosis Society

Treatments:

Estrogens